The influence of IL-12/23 inhibitors on cardiovascular safety was also compared with those of other biologics approved for the treatment of psoriasis in some trials, which reported a comparable risk of MACEs among ustekinumab, TNF-α inhibitors, and IL-17 inhibitors (Kimball et al., 2013; Ikonomidis et al., 2017; Gelfand, 2018). Here, IL17A is linked to psoriasis.